Neuland Q1FY26 Total Income at Rs.300.6 crore; EBITDA at Rs.42.1 crore

Neuland Laboratories Limited, a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services, announced financial results for the first quarter ended June 30, 2025. Despite a below-par Q1 FY26, the company anticipates healthy growth for the financial year. Investments are proceeding as planned and would be drivers of short and long term growth. The company continues to focus on cost optimization opportunities and investing in people and capabilities.